類風濕關節炎:全球醫藥品市場(2011∼2021年)

類風濕關節炎:全球醫藥品市場(2011∼2021年) 是由出版商Visiongain在2011年09月所出版的。 這份英文市場調查報告書包含138 Pages 價格從美金2642起跳。

簡介

本報告提供全球類風濕關節炎市場相關調查分析，彙整主要產品到2021年為止的收益預測，各地區趨勢，研究開發，市場競爭和機會等資料，為您概述為以下內容。

第1章 摘要整理

第2章 類風濕關節炎的簡介

• 何謂類風濕關節炎
• 關節的理解
• 類風濕關節炎的原因
• 類風濕關節炎的診斷
• 危險因素
• 類風濕關節炎的管理
• 類風濕關節炎的經濟成本
• 類風濕關節炎的全球得病率
• 類風濕關節炎發病的不確定性

第3章 類風濕關節炎的治療

• 類風濕關節炎治療所採用的藥物
• 止痛藥
• 皮質類固醇
• 抗類風濕關節炎劑
• 治療類風濕關節炎的生物製劑
• 類風濕關節炎市場上主要治療方法

第4章 全球類風濕關節炎市場:2011∼2021年

• 全球類風濕關節炎市場:2011∼2021年
• 類風濕關節炎的非生技藥品
• 類風濕關節炎的生技藥品市場預測
• 市場摘要

第5章 類風濕關節炎市場上主要藥物:2011∼2021年

• 非類固醇抗發炎藥(NSAID)
• 生技藥品

第6章 類風濕關節炎的研究開發平台:2011年

• NSAID
• 皮質類固醇
• 生技藥品

第7章 主要國家市場

• 主要國家市場
• 美國
• 日本
• 歐洲
• 新興經濟
  • 中國
  • 印度
• 其他地區
• 各國市場預測摘要

第8 主要企業

• 簡介
• Roche
• Abbott Laboratories
• Amgen
• Johnson & Johnson
• Biogen Idec

第9章 推動市場因素和阻礙因素

• SWOT分析
• 商業的推動要素
• 商業的阻礙要素
• 結論

第10章 專家的見解

第11章 結論

圖表

目錄

Abstract

Report Details

How will the market for rheumatoid arthritis treatments perform from 2011? Visiongain's report shows you potential revenues to 2021, discussing opportunities and prospects.

Discover rheumatoid arthritis drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.

See how drugs such as Celebrex, Arcoxia, Humira, Remicade, Enbrel, MabThera and Cimzia can perform to 2021, finding potential revenues. How will competition affect the market?

Discover commercial prospects for biological and non-biological drugs for rheumatoid arthritis. Receive data you need for non-steroidal anti-inflammatory drugs (NSAIDs) and other products.

There is a strong R&D pipeline for treating inflammatory diseases. We cover NSAIDs, corticosteroids and biologics for rheumatoid arthritis. Find R&D trends.

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 69 tables and charts and two research interviews (see the table of contents).

Rheumatoid Arthritis: World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages in particular:

• Find revenue predictions to 2021 for the world rheumatoid arthritis drug market and submarkets, seeing revenue growth
• Discover revenue forecasts to 2021 for leading products, assessing market potentials
• Assess leading companies, discovering their activities and outlooks
• See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
• Review R&D for treating rheumatoid arthritis, seeing pipeline trends
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• View opinion from our survey, receiving full interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions for rheumatoid arthritis, helping you to stay ahead.

Table of Contents

1. Executive Summary

• 1.1 World Rheumatoid Arthritis Treatments Market Outlook
• 1.2 Aims Scope and Format of the Report
• 1.3 Research and Analysis Methods
• 1.4 Chapter Outlines

2. Introduction to Rheumatoid Arthritis

• 2.1 What is Rheumatoid Arthritis?
• 2.2 Understanding Joints
• 2.3 What Causes Rheumatoid Arthritis?
  • 2.3.1 Overactive Immune System: The Immune Response and Inflammation Process
  • 2.3.2 Genetic Factors
  • 2.3.3 Environmental Triggers
• 2.4 Diagnosis of Rheumatoid Arthritis
  • 2.4.1 Radiographic Features of Rheumatoid Arthritis
  • 2.4.2 Blood Tests
  • 2.4.3 Disorders with Similar Symptoms
• 2.5 Disease Risk Factors
• 2.6 Managing Rheumatoid Arthritis
  • 2.6.1 Main Treatments Offered
  • 2.6.2 Other Treatments Offered
  • 2.6.3 Diet and Complementary Therapies
  • 2.6.4 Surgical Options
  • 2.6.5 Monitoring Disease Progression
• 2.7 Economic Costs of Rheumatoid Arthritis
• 2.8 World Prevalence of Rheumatoid Arthritis
• 2.9 Uncertainty on the Incidence of Rheumatoid Arthritis

3. Treatments for Rheumatoid Arthritis

• 3.1 What Drugs Are Used to Treat RA?
• 3.2 Pain Relieving Drugs
  • 3.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 3.2.2 Side-Effects of NSAIDs
• 3.3 Corticosteroids
• 3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • 3.4.1 Methotrexate
  • 3.4.2 Biologics
  • 3.4.3 Hydroxychloroquine and Sulfasalazine
  • 3.4.4 Minocycline
  • 3.4.5 Leflunomide
  • 3.4.6 Cyclosporine
  • 3.4.7 Azathioprine
• 3.5 Biologics for Rheumatoid Arthritis Treatment
  • 3.5.1 What is Tumour Necrosis Factor?
  • 3.5.2 Side-Effects of Biologics
  • 3.5.3 Combining Biologics with DMARDs
• 3.6 Key Treatments in the RA Drug Market

4. The Global Rheumatoid Arthritis Drug Market, 2011-2021

• 4.1 The Global Rheumatoid Arthritis Market, 2011-2021
• 4.2 Non-Biologics for RA
  • 4.2.1 NSAIDs: Market Forecast, 2011-2021
  • 4.2.2 Other Non-Biologics for RA: Market Forecast, 2011-2021
• 4.3 Biologics for RA: Market Forecast 2011-2021
  • 4.3.1True Contribution of Biologics in the RA Market
• 4.4 Summary of the Market

5. Main Drugs in the Rheumatoid Arthritis Market, 2011-2021

• 5.1 Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.1.1 Celebrex (Pfizer): Market Forecast, 2011-2021
    • 5.1.1.1 Development of Celebrex
  • 5.1.2 Arcoxia (Merck and Co.): Market Forecast, 2011-2021
    • 5.1.2.1 Development of Arcoxia
• 5.2 Biologics for RA Treatments
  • 5.2.1 Humira (Abbott Laboratories): Market Forecast, 2011-2021
    • 5.2.1.1 Long Term Prospects for Humira
  • 5.2.2 Remicade (Johnson and Johnson): Market Forecast, 2011-2021
    • 5.2.2.1 Long Term Prospects for Remicade
  • 5.2.3 Enbrel (Amgen; Pfizer; Takeda): Market Forecast, 2011-2021
    • 5.2.3.1 Amgen Continues to Benefit from Enbrel Sales
    • 5.2.3.2 Enbrel Sales Will Show an Initial Increase
    • 5.2.3.3 Study Eases Fears of TNF Blocker Cancer Risk
    • 5.2.3.4 New Enbrel Delivery System
    • 5.2.3.5 Sales of Enbrel Will Eventually Decline
    • 5.2.3.6 Enbrel Faces Competition from Several Other Biotech Drugs
  • 5.2.4 MabThera (Rituxan in the US - Roche; Biogen Idec): Market Forecast, 2011-2021
    • 5.2.4.1MabThera: Leading Biologic for RA
  • 5.2.5 Orencia (Bristol-Myers Squibb): Market Forecast, 2011-2021
    • 5.2.5.1 Orencia: New Biologic for RA
  • 5.2.6 Actemra (Roche): Market Forecast, 2011-2021
    • 5.2.6.1 Actemra Will Achieve Growth
  • 5.2.7 Cimzia (UCB): Market Forecast, 2011-2021
    • 5.2.7.1 Cimzia: Forecast and Analysis, 2011-2021
  • 5.2.8 Kineret (Biovitrium): Future Prospects
  • 5.2.9 Simponi (Johnson and Johnson): Future Prospects

6. R&D Pipeline for Rheumatoid Arthritis Drugs, 2011

• 6.1 R&D Pipeline: NSAIDs for Rheumatoid Arthritis, 2011
  • 6.1.1 Famotidine + Ibuprofen (Horizon)
  • 6.1.2 Ibuprofen-PC (PLx Pharma)
  • 6.1.3 Apricoxib (Tragara; Daiichi Sankyo)
  • 6.1.4 CEP 33222 (Cephalon; Acusphere)
• 6.2 R&D Pipeline: Corticosteroids for Rheumatoid Arthritis, 2011
  • 6.2.1 Lodotra (Horizon; SkyePharma)
• 6.3 R&D Pipeline: Biologics to Treat Rheumatoid Arthritis, 2011
  • 6.3.1 Denosumab (Amgen)
  • 6.3.2 Fostamatinib (AstraZeneca)
  • 6.3.3 Tofacitinib (Pfizer)
  • 6.3.4 Ofatumumab (Genmab; GSK)
  • 6.3.5 Masitinib (AB Science)
  • 6.3.6 Belimumab (GSK; Human Genome Sciences)
  • 6.3.7 Canakinumab (Novartis)
  • 6.3.8 Baminercept Alfa (Biogen Idec)
  • 6.3.9 Ocrelizumab (Roche)
  • 6.3.10 Sarilumab (Regeneron; Sanofi)
  • 6.3.11 dnaJP1 (Adeona)
  • 6.3.12 T-5224 (Roche; Toyoma Chemicals)
  • 6.3.13 Anti- BAFF Monoclonal Antibody (Eli Lilly)
  • 6.3.14 Olokizumab (UCB)
  • 6.3.15 Anti-IL-17 Monoclonal Antibody (Eli Lilly)
  • 6.3.16 JAK1/JAK2 Inhibitor (Eli Lilly)
  • 6.3.17 Sirukumab (Johnson and Johnson)
  • 6.3.18 INCB018424 (Incyte Corporation)
  • 6.3.19 ALD 518 (Bristol Myers Squibb; Alder Biopharmaceuticals)
  • 6.3.20 GSK3152314A (GlaxoSmithKline)
  • 6.3.21 RPI-MN (ReceptoPharm)
  • 6.3.22 MT203 (Nycomed)

7. Leading National Markets for Rheumatoid Arthritis Treatments, 2011-2021

• 7.1 Leading National Markets for Rheumatoid Arthritis, 2010-2021
• 7.2 The US Rheumatoid Arthritis Market, 2011-2021
• 7.3 The Japanese Rheumatoid Arthritis Market, 2011-2021
• 7.4 The Leading European Markets for Rheumatoid Arthritis Treatments, 2011-2021
• 7.5 Rheumatoid Arthritis Drug Market in Emerging Economies, 2011-2021
• 7.5.1 The Chinese Rheumatoid Arthritis Market, 2011-2021
• 7.5.2 The Indian Rheumatoid Arthritis Market, 2011-2021
• 7.6 Rheumatoid Arthritis Treatments in the Rest of the World, 2011-2021
• 7.7 Summary of National Market Forecasts

8. Leading Companies in the Rheumatoid Arthritis Drug Market, 2011

• 8.1 Introduction
• 8.2 Roche
• 8.3 Abbott Laboratories
• 8.4 Amgen
• 8.5 Johnson & Johnson
• 8.6 Biogen Idec

9. Drivers and Restraints in the Rheumatoid Arthritis Drug Market

• 9.1 SWOT Analysis of the RA Drug Market
• 9.2 Commercial Drivers in the RA Drug Market
  • 9.2.1 The Biological Drug Market for RA is Well-Established
  • 9.2.2 New Product Development Will Drive the RA Market
  • 9.2.3 Rising Prevalence of RA Will Enhance Market Growth
  • 9.2.4 Small Molecules Will Have a Positive Impact on RA Treatments
  • 9.2.5 Revised Treatment Classification Criteria Will Make Diagnosis Easier
• 9.3 Commercial Restraints in the RA Drug Market
  • 9.3.1 Biological Drugs - Too Costly in Most Countries?
  • 9.3.2 The Biological Drug Industry - Insufficiently Dynamic?
  • 9.3.3 Unmet Clinical Needs in Rheumatoid Arthritis Treatment Will Slow Growth
  • 9.3.4 Biosimilar Competition May Restrain the RA Market for Biologics
  • 9.3.5 Side-Effects and Costly Treatments
  • 9.3.6 Inadequate Reimbursement for Biologics Will Hamper RA Market Growth
• 9.4 Concluding Remarks

10. Research Interviews

• 10.1 Interview 1: Dr Yusuf Yazici, MD, Assistant Professor, Department of Medicine-Rheumatology and Hospital for Joint Diseases and Medicine, New York University
  • 10.1.1 Opinion on the Key Unmet Needs for RA Treatments
  • 10.1.2 Opinions on Current Treatments
  • 10.1.3 Views on Abatacept: New Biologic for RA
  • 10.1.4 Key Challenges: Development and Uptake of Abatacept
  • 10.1.5 Views on Cimzia
  • 10.1.6 Treatments in the R&D Pipeline
  • 10.1.7 Views on the Prevalence of RA
• 10.2 Interview 2: A Professor Working in Rheumatology
  • 10.2.1 Views on the Prevalence of RA
  • 10.2.2 Views on Anti-TNF Therapies for RA
  • 10.2.3 Opinion on Biosimilars
  • 10.2.4 Key Challenges in the Market
  • 10.2.5 Key Treatment Goals

11. Conclusions

• 11.1 The RA Market - Revenue Growth
• 11.2 Non-Biologic Treatments
• 11.3 Biologic Treatments
• 11.4 Improvements Needed in RA Treatments
• 11.5 Future Rheumatoid Arthritis Treatments: R&D Efforts Promising
• 11.6 The RA Treatments Sector: Looking into the Future Confidently

List of Tables

• Table 2.1 Diseases with Symptoms Similar to RA, 2011
• Table 3.1 Main Treatments for RA, 2011
• Table 3.2 Revenues ($bn) for Main Biologics (All Inflammatory Indications), 2010
• Table 4.1 The Global RA Drug Market Forecast ($bn), 2010-2021
• Table 4.2 Total NSAIDs Market for RA Treatments ($bn), 2010-2021
• Table 4.3 Other Non-Biologics Market for RA Treatments ($bn), 2010-2021
• Table 4.4 Total Revenue for Main Biologics for All Inflammatory Conditions: Market Forecast ($bn), 2010-2021
• Table 4.5 Estimated Contribution by Biologics for RA: Market Forecast ($bn), 2010-2021
• Table 4.6 RA Treatments: Forecasts for Submarkets ($bn), 2010-2021
• Table 4.7 World Rheumatoid Arthritis Treatments by Submarket ($bn), 2010, 2015 and 2021
• Table 5.1 World Celebrex Revenue Forecast ($bn), 2010-2021
• Table 5.2 World Arcoxia Revenue Forecast ($bn), 2010-2021
• Table 5.3 NSAID Market Forecasts for RA Treatment ($bn), 2010-2021
• Table 5.4 World Humira Revenue Forecast ($bn), 2010-2021
• Table 5.5 World Remicade Revenue Forecast ($bn), 2010-2021
• Table 5.6 World Enbrel Revenue Forecast ($bn), 2010-2021
• Table 5.7 World MabThera Revenue Forecast ($bn), 2010-2021
• Table 5.8 World Orencia Revenue Forecast ($bn), 2010-2021
• Table 5.9 World Actemra Revenue Forecast ($bn), 2010-2021
• Table 5.10 World Cimzia Revenue Forecast ($bn), 2010-2021
• Table 5.11 Biologics: Revenue Forecasts ($bn), 2010-2021
• Table 6.1 R&D Pipeline: NSAIDs and Painkillers, 2011
• Table 6.2 R&D Pipeline: Corticosteroids, 2011
• Table 6.3 R&D Pipeline: Biologics, 2011
• Table 7.1 Leading National Revenues ($bn) and Market Shares (%) for RA in 2010, 2015 & 2021
• Table 7.2 US RA Treatments Market Forecast ($bn), 2010-2021
• Table 7.3 Japanese RA Treatments Market Forecast ($bn), 2010-2021
• Table 7.4 EU5 Countries: RA Treatment Market Forecasts ($bn), 2010-2021
• Table 7.5 Emerging Economies - China and India: RA Treatment Market Forecasts ($bn), 2010-2021
• Table 7.6 RA Market in The Rest of The World ($bn), 2010-2021
• Table 7.7 Leading National Markets for RA Treatments ($bn), 2010-2021
• Table 8.1 Revenues ($bn) and Market Shares (%) of Leading Organisations for Biologics, 2010
• Table 8.2 Roche: Revenues ($bn) for Key Biologics, 2010
• Table 8.3 Abbott Laboratories: Revenue ($bn) for Key Biologic, 2010
• Table 8.4 Amgen: Revenue ($bn) for Key Biologic, 2010
• Table 8.5 Johnson and Johnson: Revenues ($bn) for Key Biologics, 2010
• Table 8.6 Biogen Idec: Revenue ($bn) for Key Biologic, 2010
• Table 9.1 SWOT Analysis of the Rheumatoid Arthritis Drug Market, 2011-2021

List of Figures

• Figure 4.1 The Global RA Drug Market Forecast ($bn), 2010-2021
• Figure 4.2 Total NSAIDs Market for RA Treatments ($bn), 2010-2021
• Figure 4.3 Other Non-Biologics Market for RA Treatments ($bn), 2010-2021
• Figure 4.4 Estimated Contribution by Biologics for RA: Market Forecast ($bn), 2010-2021
• Figure 4.5 World RA Treatments: Market Shares (%) by Sub Market, 2010
• Figure 4.6 World RA Treatments: Market Shares (%) by Sub Market, 2015
• Figure 4.7 World RA Treatments: Market Shares (%) by Sub Market, 2021
• Figure 5.1 World Celebrex Revenue Forecast ($bn), 2010-2021
• Figure 5.2 World Arcoxia Revenue Forecast ($bn), 2010-2021
• Figure 5.3 World Humira Revenue Forecast ($bn), 2010-2021
• Figure 5.4 World Remicade Revenue Forecast ($bn), 2010-2021
• Figure 5.5 World Enbrel Revenue Forecast ($bn), 2010-2021
• Figure 5.6 World MabThera Revenue Forecast ($bn), 2010-2021
• Figure 5.7 World Orencia Revenue Forecast ($bn), 2010-2021
• Figure 5.8 World Actemra Revenue Forecast ($bn), 2010-2021
• Figure 5.9 World Cimzia Revenue Forecast ($bn), 2010-2021
• Figure 7.1 Leading National Market Shares (%) for RA, 2010
• Figure 7.2 Leading National Market Shares (%) for RA, 2015
• Figure 7.3 Leading National Market Shares (%) for RA, 2021
• Figure 7.4 US RA Treatments Market Forecast ($bn), 2010-2021
• Figure 7.5 Japanese RA Treatments Market Forecast ($bn), 2010-2021
• Figure 7.6 US and Japanese RA Treatment Market Forecasts ($bn), 2010-2021
• Figure 7.7 EU5 Countries: RA Treatment Market Forecasts ($bn), 2010-2021
• Figure 7.8 Emerging Economies - China and India: RA Treatments Market Forecast ($bn), 2010-2021
• Figure 7.9 RA Market in the Rest of The World ($bn), 2010-2021
• Figure 8.1 Market Shares (%) of Leading Organisations for Biologics Contributing Towards RA Treatments, 2010
• Figure 8.2 Roche: Sales Shares (%) for Key Biologics, 2010
• Figure 8.3 Abbott Laboratories: Sales Share (%) for Key Biologic, 2010
• Figure 8.4 Amgen: Sales Share (%) for Key Biologic, 2010
• Figure 8.5 Johnson and Johnson: Sales Shares (%) for Key Biologics, 2010
• Figure 8.6 Biogen Idec: Sales Share (%) for Key Biologic, 2010

Companies Listed

• AB Science
• Abbott Laboratories
• Acusphere
• Adeona Pharmaceuticals
• Alder Biopharmaceuticals
• American College of Rheumatology
• Amgen
• Arthritis Foundation of America
• Astellas
• AstraZeneca
• Biogen Idec
• Biovitrum
• Bristol-Myers Squibb (BMS)
• Celgene
• Centocor Ortho Biotech
• Cephalon
• Chugai
• Daiichi Sankyo
• Eisai
• Eli Lilly
• European Commission
• European League Against Rheumatism (EULAR)
• European Medicines Agency (EMA/EMEA)
• Food and Drug Administration (US FDA)
• GE Healthcare
• Genentech (owned by Roche)
• Genmab
• Genzyme (owned by Sanofi)
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Horizon Pharma
• Human Genome Sciences
• Imperial College London
• Incyte Corporation
• Japanese Ministry of Health, Labour and Welfare
• Johnson & Johnson
• Kitasato University
• Kobe University
• mAb Discovery
• Medicare
• Merck & Co.
• Mitsubishi Tanabe Pharma
• National Health Service (UK NHS)
• National Rheumatoid Arthritis Society (NRAS)
• New York University
• Novartis
• Nycomed
• Otsuka Pharmaceutical
• Pfizer
• PharmaNet Development Group
• PLx Pharma
• Radient Pharmaceuticals
• ReceptoPharm
• Regeneron
• Rigel Pharmaceuticals
• Roche
• Rules-Based Medicine
• Sanofi
• Schering-Plough (now part of Merck and Co.)
• SkyePharma
• Teva
• Takeda
• Toyoma Chemical
• Tragara Pharmaceuticals
• UCB
• World Health Organization (WHO)
• Wyeth (now part of Pfizer)
• Zenyaku Kogyo

相關商品

骨頭疾病治療相關市場調查報告書

全球及中國的骨質疏鬆症治療藥物市場:市場規模·市場趨勢·市場預測(2010-2015年)
Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
價格 : US $ 2395
出版日期 : 2012年01月

中國的骨質疏鬆症市場分析與預測(2007年∼2015年)
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
價格 : US $ 1500
出版日期 : 2012年01月

全球肌肉骨骼疾病治療藥物的市場(到2017年為止)
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
價格 : US $ 3500
出版日期 : 2012年01月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!